3. 脊髄性筋萎縮症 Spinal muscular atrophy Clinical trials / Disease details
臨床試験数 : 237 / 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002822-78-DE (EUCTR) | 09/01/2006 | 21/11/2005 | Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GH | Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GH | Spinal muscular atrophy (SMA) is an autosomal recessive disease. Due to the genetic defect, a molecule called spinal motor neuron” (SMN) protein is lacking, resulting in muscle weakness. In SMAs muscle weakness is found most often at the level of proximal muscles. The disease is life-threatening and chronically debilitating. | Trade Name: Norditropin SimpleXx Product Name: Norditropin SimpleXx 15 mg/1.5 ml Product Code: GH INN or Proposed INN: Somatropin Other descriptive name: Norditropin SimpleXx | Klinik Neuropädiatrie und Muskelkrankheiten | NULL | Not Recruiting | Female: yes Male: yes | 20 | Germany |